Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.61 |
| ▸ | AKT1 | P31749 | 11/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | PRKCB | P05771 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | PRKCH | P24723 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.57 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.57 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.54 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.48 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.48 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114219 | 0.85 | AKT2 (0.46) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL1385812 | 0.82 | AKT2 (0.67) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL1976418 | 0.80 | AKT2 (0.70) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL1977183 | 0.77 | AKT2 (0.62) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL1978297 | 0.76 | HSD17B10 (0.46) | — | |
| SCHEMBL1977797 | 0.76 | AKT2 (1.00) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL2797505 | 0.76 | AKT2 (1.00) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL1981729 | 0.76 | AKT2 (1.00) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL27674398 | 0.76 | AKT2 (0.74) | AKT2AKT1PRKCDPRKD3PRKCG | |
| SCHEMBL13114220 | 0.76 | AKT2 (0.74) | AKT2AKT1PRKCDPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-1933832-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| CN-1922148-A | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2007-02-28 | — | — | CN | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 114/4885AKT1 91/4885PRKCD 105/4885 |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, GRK2 | AKT2 37/4885AKT1 40/4885PRKCD 410/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 114/4885AKT1 91/4885PRKCD 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.